26th Russian Education Fair held in Delhi; main focus on medical education
The Russian Centre for Science and Culture, in collaboration with Rus-Education, hosted the 26th Russian Education Fair in New Delhi on Saturday. The event primarily highlighted opportunities in medical education in Russia and featured representatives from 10 leading Russian universities offering undergraduate courses in medical sciences (MBBS).
The event saw representation from prominent Russian universities, including Orenburg State Medical University, Perm State Medical University, BB Gorodovikov Kalmyk State University, Pskov State University, and Mari State University, among others.
Earlier this month, the Russian Education Fair was held in Mumbai, Trivandrum, Kolkata, Patna, Ahmedabad, and Indore. The fair will next be hosted in Chandigarh and then in Jaipur.
Speaking at the event, Dr Elena Remizova, Director, Russian House in New Delhi, said: 'Education is one of the strongest pillars of Indo-Russian cooperation. Through initiatives like the Russian Education Fair, we aim to empower Indian students with access to world-class universities in Russia.'
Delegates from these select universities interacted with students, sharing insights into the admission process, course structure, academic programs offered, along with support facilities such as infrastructure, hostel facilities, and overall student life in Russia.
'Preferred destination for Indian medical aspirants'
Speaking to the indianexpress.com, the vice chancellor of Mari State University explained that there is no blanket cap on admissions for Indian students in Russian universities, unlike in several Western countries where restrictive immigration policies and admission limits are impacting international student intake. 'The Russian Federation will make every effort to accept everyone and guarantee them a decent education,' she said, while emphasising that quality assurance must go hand-in-hand with expanding access.
According to data from the Ministry of External Affairs (MEA), the number of Indian students in Russia increased from 19,784 in 2022 to 23,503 in 2023 and further to 31,444 in 2024, reflecting a steady rise in enrolments, particularly in medical education.
No cap, but quality first
Responding to questions about the increasing attractiveness of Russia as an alternative destination, the vice chancellor said that while other countries are tightening their immigration and education policies, Russia is choosing a more open path. 'We are not looking at limiting the number of seats,' she noted. Instead, the Russian government and universities are actively working to increase the number of seats for Indian students, especially in medical programs.
However, this expansion, she cautioned, is not without checks. 'We have to guarantee the quality of medical education that we are providing to Indian students,' she added. This is crucial because many Indian students pursuing MBBS in Russia eventually sit for India's licensing examination, which determines their eligibility to practice back home. He added that Russian universities are not only focusing on completing the curriculum but also preparing students specifically for the Indian licensing exams.
She acknowledged that reducing seat availability might be an easier route, but maintaining and improving educational standards while expanding capacity is the more challenging and more important path. 'To increase the number of seats and to maintain that quality of education that the universities have a legacy of, it is a more difficult thing, and we are taking all the measures,' she said.
Medical study demand
The vice chancellor revealed that last year, around 34,000 Indian students travelled to Russia for higher education – the vast majority of them for medical studies. 'Ninety-nine per cent students travel for medical courses only, because for engineering and other courses there is not such demand,' she explained. This demand stems from the imbalance in India's own medical education system, where around 24-25 lakh students appear for the NEET exam every year, but only about 1 lakh MBBS seats are available across both government and private institutions.
Looking ahead, Russian universities are preparing to accommodate over 40,000 Indian students in medical programs this year alone.
Why Indian students prefer Russia
When asked about the factors attracting Indian students to Russia, the vice chancellor pointed to a blend of historical, economic, and cultural reasons.
'The first aspect is the long-standing diplomatic relations between the two countries,' she said, noting that the first Indian student went to Russia in 1948, and the first medical student followed in 1968. This continuity, she added, has ensured that geopolitical or political disturbances have never disrupted the educational journeys of Indian students in Russia, a key concern for families when choosing a destination.
Secondly, affordability is a major draw. In India, private medical education can cost over Rs 1 crore, whereas in Russian universities, the entire six-year MBBS course costs between Rs 18 lakh and Rs 45 lakh, making it far more accessible.
In addition, many Russian universities have adapted their infrastructure to cater specifically to Indian students. 'There are separate hostels for Indian students, separate arrangements for boys and girls as per the requirements of the parents here,' she said. Facilities such as Indian mess, departments for cultural adaptation, and special safety protocols – including 24-hour CCTV surveillance and police patrolling make Indian students and their families feel more at ease.
Lastly, the global recognition of Russian medical degrees means that graduates can pursue careers not just in India but also in countries like the US and the UK.
Is there a cap on the number of students that can be admitted?
When asked whether there is a fixed cap on the number of Indian students each university can admit, the vice chancellor stated that individual universities set their own intake limits based on available infrastructure and teaching staff. 'Some universities have 500 seats, some universities have 200 seats,' she said. The vice chancellor also mentioned that a new university has entered the Russian-Indian education market this year, starting with an initial intake of 100 Indian students to test its facilities and systems.
'Universities have their own set of guidelines according to which they prescribe the number of students they can take,' she concluded.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
38 minutes ago
- Time of India
BRS MLA from Hyderabad's Jubilee Hills, Maganti Gopinath passes away
HYDERABAD: BRS MLA from Jubilee Hills, Maganti Gopinath, passed away at a corporate hospital on Sunday morning. Gopinath , who suffered a massive heart attack on June 5, was undergoing treatment and breathed his last at 5.45 am. The three-time MLA from Jubilee Hills had been suffering from various health issues over the past year. The 62-year-old Gopinath, who was serving as the president of the Greater Hyderabad BRS wing and MLA of Jubilee Hills Assembly constituency, began his political journey with the Telugu Desam Party in 1983. He served as president of the TDP youth wing, Telugu Yuvatha, from 1985 to 1992 and also held the post of TDP Hyderabad district president. Gopinath worked as director of the then Hyderabad Urban Development Authority (HUDA) for two years, from 1987 to 1989. He was also a member of the Hyderabad District Consumer Forum. As an MLA, Gopinath won for the first time in 2014 on a TDP ticket and later joined the BRS. He went on to contest and win on a BRS ticket again in the 2018 and 2023 Assembly polls. In the 2023 election, he defeated former Indian cricket captain Mohd Azharuddin by a margin of 16,000 votes. He is survived by his wife, Sunitha, son Vatsalyanath, and two daughters, Akshata and Disira. BRS president K Chandrasekhar Rao, working president K T Rama Rao, Union minister G Kishan Reddy, and former ministers T Harish Rao and Talasani Srinivas Yadav were among several leaders who condoled the MLA's death.
Time of India
3 hours ago
- Time of India
Trump is forcing us to confront the myth of the American dream itself
At the height of the Covid pandemic, a philosopher and an academic in the US began writing to each other discussing everything from careers to chronic pain. These letters have now taken the shape of 'The End Doesn't Happen All At Once: A Pandemic Memoir'. Tired of too many ads? go ad free now In a conversation with Shruti Sonal , Ragini Tharoor Srinivasan, an English professor, and Chi Rainer Bornfree , who co-founded a school for activists, talk about the Covid years and the impact of Trump You've spoken about how writing about the pandemic — something people have been eager to forget — felt like looking directly into the sun. What drove you to publish this series of letters? R: This is a deeply lived-in book for me — one that allowed me to attend, in both an intimate and expansive way, to what it meant to be alive during a time of dramatic social, geopolitical, and technological upheaval. During the pandemic, we were all aware of tragedies unfolding on multiple scales, even as we experienced moments of joy, beauty, and connection in our own lives. How could we hold all of that complexity together? How might we stay with it, rather than turn away? We published this memoir as an offering to readers who might be moved by the way we valued our own and each other's lives, and who might find strength in what one reader described as our 'deep and curious' friendship. It's important to remember those years not only because they were marked by loss and devastation — much of which has not yet been adequately grieved — but also because they revealed new possibilities, moments of radical awakening, and potential solidarities. Covid and measles cases are rising, and vaccination rates are falling. Do you think any lessons have been learnt? C: There was learning — briefly — but after the initial shock, there was much more forgetting and active suppression of what we learned. Tired of too many ads? go ad free now With cases rising in the US of bird flu and measles, I hope that masking and other acts to care for public health will surface quickly from our societies' muscle-memory. But I worry that, like someone who persistently misspells a common word, too many Americans are clinging stubbornly to the wrong lessons from the pandemic: that we can't trust the experts, that it's 'us against them', or that 'what doesn't kill you makes you stronger'. Ragini, in one letter, you write about the dilemmas of being an Indian writing in English, a colonial bequest and the language of the elites. How do you see the current push for translated literature in India vis-a-vis the future of Indian writing in English? It's a very exciting time for Indian literature — from the global success of translated works like Banu Mushtaq's 'Heart Lamp' to the growing practice of literary translation between Indian languages that no longer relies on English as a kind of neutral mediator, as was so often the case in the past. As an Indian American who writes in English and works primarily on the contemporary, I'm especially interested in the decentering — even provincialisation — of Indian diasporic writers, Anglo-American literatures, and Anglophone ambassadors for India in the West. In a very real sense, India no longer needs English (the language or its writers) to speak for it. At the same time, it would be foolish to deny that English is already an Indian language, with its own indigenous life. In my recent book on literary studies, 'Overdetermined', I examine how Indian English writing is made 'American', so to speak, through its circulation in ethnic and postcolonial literature classrooms. In one chapter, I argue that the challenge now is to be careful not to allow demotic, so-called 'vernacular' English texts to stand in for — or crowd out — the urgent need to read and publish works in translation. As an academic in the US, how do you see the Trump administration's assault on universities? Is this the beginning of the end of the great American dream for many immigrant students? R: In many ways, the violence the Trump administration has inflicted on US higher education is only accelerating a trend that's been underway since the turn of the century: immigrant students, especially from India and China, choosing to return 'home' because the future — politically, economically, and intellectually — is increasingly centered in a rising Asia, in a post-American world. But yes, in another sense, it does feel like the beginning of the end of the American dream for many immigrant students. My parents came to the US for college and graduate school in the early 1980s, and it's hard to imagine their particular trajectories being possible today. If there's a silver lining, perhaps it's that we're being forced to confront the myth of the American dream itself — recognising that it was never universally accessible, and that many have experienced it as a nightmare. As an academic, I still hope we can preserve what's best about our universities: as spaces of meaningful knowledge production and critical inquiry, and as institutions committed to broad-based access and opportunity. Chi, you run The Activist Graduate School (AGS). What role is it playing as students in the US get arrested and deported for their activism? AGS is an experimental set of courses on activism that my partner Micah Bornfree and I started because we saw that movements like Occupy Wall Street and Black Lives Matter had achieved huge mobilisation very quickly, but failed to realise enduring material transformations. We wanted to enable activists on and off campus to break with groupthink and tired modes of protest, and innovate new methods of seizing power. Ragini and I both went to the University of California, Berkeley, the birthplace of the Free Speech Movement in the 1960s which paved the way for much student activism today. Those rights are now being eroded.
Time of India
4 hours ago
- Time of India
Weight-loss drug bulks up sales as patients upgrade dosage
Eli Lilly's weight-loss and diabetes drug, Mounjaro, has rapidly gained popularity in India, achieving Rs 24 crore in sales within three months. Young adults in their 30s and 40s are showing significant interest, with many upgrading to higher doses. While experts acknowledge its potential in addressing obesity, they caution about long-term efficacy, side effects, and affordability for the Indian population. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Sales of Mounjaro, Eli Lilly 's blockbuster weight-loss and diabetes drug, have touched Rs 24 crore within three months of its India launch, making it one of the most popular and fastest adopted new drugs in the country, with many people in their thirties and early forties showing sales grew 60% month on month to Rs 12.60 crore last month from Rs 7.87 crore in April, with the 5 mg injections accounting for Rs 7.53 crore—up 145% from Rs 3.08 crore in the previous month, data from industry tracker PharmaTrac showed. This indicates that patients are upgrading to higher doses after taking an initial base dose of 2.5 mg, experts doctors recommend a dose escalation to 5 mg after one month of starting the medication, depending on side effects. Mounjaro is currently available in 2.5 mg and 5 mg injections in India. Sales of 2.5 mg injections rose to Rs 5.08 crore in May from Rs 4.80 crore in April and Rs 1.42 crore in March, when it was launched, according to PharmaTrac data.'Our data indicates patients upgrading to higher dose after four weeks as well as new patients onboarding on lower dose,' said Sheetal Sapale, vice president, commercial, at endocrinologists said many people in their 30s and early 40s are reaching out to doctors to check if they could use the medication to lose weight.'There are many young people asking me if they could use the drug,' said Vyankatesh Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai. He said Indian patients are responding well to tirzepatide (Mounjaro).'Clinical trials conducted previously on Indian obese diabetes patients have shown good weight loss benefits at more than 20% as well as good sugar control,' Shivane said. 'Both semaglutide (Novo Nordisk's Wegovy) and tirzepatide have completed cardiovascular safety trials and have shown added benefits of reduction of cardiovascular events in Type 2 diabetes patients,' he drugmaker Novo Nordisk is expected to launch its blockbuster weight-loss drug Wegovy in India this year. Doctors said medications like Mounjaro and Wegovy could prove an actionable remedy in a country of 80 million obese they cautioned that it would take four to six months to assess their effect on a larger Indian population regarding actual weight loss efficacy, potential weight regain after stopping the medication, and side to Shivane, clinical trails have shown weight regain of 5-7% once the drug is stopped. 'That is where patients will need counselling in order to adopt a healthier lifestyle including healthy dietary habits and regular exercise,' he Kumar Sinha, consultant physician at Mumbai-based WeCare Wellness, said, 'The molecule is good. Global studies suggest there are patients who have benefitted from it, but there are also those who have dropped out due to side effects that are mostly gastrointestinal in nature.' Commonly reported side effects include nausea, vomiting, diarrhoea, constipation and abdominal pain. Sinha said it will take 3-4 months to tell how the drug is working on Indian patients. 'One also has to look at the affordability issue,' he added. In India, Mounjaro is priced at Rs 3,500 for a 2.5 mg vial and Rs 4,375 for a 5 mg vial, which translates to Rs 14,000-17,500 per month, depending on the weekly dose. This means a six month treatment could cost about Rs 1 to a recent study published in leading medical journal Lancet, 70% of India's urban population is classified as obese, or overweight.'Obesity is like a pandemic in India and diabetes is very common and it is one of the useful drugs,' Anurag Lila, visiting consultant endocrinologist at Dr LH Hiranandani Hospital in Mumbai, told ET in a recent interaction.
